Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-10T21:06:07.787Z Has data issue: false hasContentIssue false

Chapter 10 - Botulinum Neurotoxin in Oromandibular Dystonia

Published online by Cambridge University Press:  02 November 2023

By
Roongroj Bhidayasiri ,
Suppata Maytharakcheep  and
Daniel Truong
Edited by
Daniel Truong ,
Dirk Dressler ,
Mark Hallett ,
Christopher Zachary  and
Mayank Pathak
Daniel Truong
Affiliation:
University of California, Riverside
Dirk Dressler
Affiliation:
Hannover Medical School
Mark Hallett
Affiliation:
National Institutes of Health (NIH)
Christopher Zachary
Affiliation:
University of California, Irvine
Mayank Pathak
Affiliation:
Truong Neuroscience Institute
Get access

Summary

Oromandibular dystonia (OMD) is a form of focal dystonia that involves the masticatory, lower facial, labial and lingual musculature affected by the trigeminal, facial and hypoglossal cranial nerves. OMD can be classified into various subtypes, which include jaw-opening, jaw-closing, jaw-deviating, lingual, perioral and/or pharyngeal dystonia. Dystonic spasms may result in clenching, or trismus; grinding of the teeth, or bruxism; tongue thrusting; lip pursing; and other movements.

Evidence-based reviews and clinical experience strongly regard botulinum neurotoxin (BoNT) injection as the first-line treatment for OMD. Patients with OMD require careful examination to determine the particular muscles involved and their pattern of contraction to enable proper selection and targeting for BoNT injection. This chapter enumerates the particular muscles involved in each subtype of OMD, discusses localization and approach for injection and use of guidance techniques where applicable, and tabulates typical dose ranges for different formulations of BoNT. Typical adverse events and techniques to avoid them are discussed.

Keywords

Oromandibular dystoniaMeige syndromejaw clenchingjaw openinglingual dystoniaperioral dystoniapharyngeal dystoniatrismusbruxismbotulinum neurotoxinBoNT
Type
Chapter
Information
Manual of Botulinum Toxin Therapy , pp. 73 - 81
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Benecke, R, Frei, K, Comella, CL (2009). Treatment of cervical dystonia. In Truong, D, Dressler, D, Hallett, M (eds.) Manual of Botulinum Toxin Therapy. Cambridge: Cambridge University Press, pp. 29–42.Google Scholar
Blitzer, A, Brin, MF, Greene, P E, Fahn, S (1989). Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol, 98, 93–7. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2916831Google Scholar
Bhidayasiri, R, Cardoso, F, Truong, DD (2006). Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol, 13(Suppl. 1) 21–9. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16417594CrossRefGoogle ScholarPubMed
Brin, MF, Fahn, S, Moskowitz, C et al. (1987). Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord, 2, 237–54.CrossRefGoogle ScholarPubMed
Clemente, C (1984). Muscles and fasciae. In Clemente, C (ed.) Gray’s Anatomy, 13th ed. Philadelphia: Lea & Feabiger, pp. 429–605.Google Scholar
Comella, CL (2018). Systematic review of botulinum toxin treatment for oromandibular dystonia. Toxicon, 147, 96–9. https://doi.org/10.1016/j.toxicon.2018.02.006Google Scholar
Dadgardoust, PD, Rosales, RL, Asuncion, RM, Dressler, D (2019). Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis. J Neural Transm (Vienna), 126, 141–8. https://doi.org/10.1007/s00702–018-1960-7Google ScholarPubMed
Dressler, D, Altavista, MC, Altenmueller, E et al. (2021). Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm (Vienna), 12, 321–35. https://doi.org/10.1007/s00702–021-02312-4Google Scholar
Gonzalez-Alegre, P, Schneider, R L, Hoffman, H (2014). Clinical, etiological, and therapeutic features of jaw-opening and jaw-closing oromandibular dystonias: a decade of experience at a single treatment center. Tremor Other Hyperkinet Mov (N Y), 4, 231. https://doi.org/10.7916/D8TH8JSMCrossRefGoogle Scholar
Hallett, M, Albanese, A, Dressler, D et al. (2013). Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon, 67, 94–114. https://doi.org/10.1016/j.toxicon.2012.12.004CrossRefGoogle ScholarPubMed
Hassell, TJW, Charles, D (2020). Treatment of blepharospasm and oromandibular dystonia with botulinum toxins. Toxins, 12. https://doi.org/10.3390/toxins12040269CrossRefGoogle ScholarPubMed
Hermanowicz, N, Truong, DD (1991). Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope, 101, 1216–18. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1943423CrossRefGoogle ScholarPubMed
Jankovic, J, Orman, J (1987). Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology, 37(4), 616–23.CrossRefGoogle ScholarPubMed
www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3504553Google Scholar
Kamburoglu, K, Sonmez, G, Nalcaci, R, Yurttutan, E, Tuzunel, AO (2019). Ultrasonographic evaluation of the masseter muscle before and after botulinum toxin injection in patients with bruxism. Oral Surg Oral MedOral Pathol Oral Radiol, 128, e174. https://doi.org/https://doi.org/10.1016/j.oooo.2019.01.059CrossRefGoogle Scholar
Lo, SE, Gelb, M, Frucht, SJ (2007). Geste antagonistes in idiopathic lower cranial dystonia. Mov Disord, 22, 1012–17. https://doi.org/10.1002/mds.21149Google Scholar
Ma, H, Qu, J, Ye, L, Shu, Y, Qu, Q (2021). Blepharospasm, oromandibular dystonia, and Meige syndrome: clinical and genetic update. Front Neurol, 12, 630221. https://doi.org/10.3389/fneur.2021.630221Google Scholar
Nastasi, L, Mostile, G, Nicoletti, A et al. (2016). Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. J Neurol, 263(9), 1702–8. https://doi.org/10.1007/s00415–016-8185-1CrossRefGoogle ScholarPubMed
Scorr, LM, Factor, SA, Parra, SP, et al. (2021). Oromandibular dystonia: a clinical examination of 2,020 cases. Front Neurol, 12, 700714. https://doi.org/10.3389/fneur.2021.700714Google Scholar
Sinclair, CF, Gurey, LE, Blitzer, A (2013). Oromandibular dystonia: long-term management with botulinum toxin. Laryngoscope, 12, 3078–83. https://doi.org/10.1002/lary.23265Google Scholar
Tan, EK, Jankovic, J (1999). Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology, 53, 2102–7. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10599789Google Scholar
Tan, EK, Jankovic, J (2000). Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry, 68, 186–90. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10644785CrossRefGoogle ScholarPubMed
Van den Bergh, P, Francart, J, Mourin, S, Kollmann, P, Laterre, EC (1995). Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve, 18, 720–9. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7783762CrossRefGoogle ScholarPubMed
Yoshida, K (2019). Botulinum neurotoxin therapy for lingual dystonia using an individualized injection method based on clinical features. Toxins, 11. https://doi.org/10.3390/toxins11010051Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×